Sudden cardiac death risk factors in patients with heart failure treated with carvedilol

Kardiologia Polska

Volumn 65, Issue 12, 2007, Pages 1417-1422

  Nessler, Jadwiga ^a   Nessler, Bohdan ^a   Kitliński, Mariusz ^b,c   Libionka, Anna ^a   Kubinyi, Aleksander ^a   Konduracka, Ewa ^a   Piwowarska, Wiesława ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Szpital Uniwersytecki   (Sweden)

Author keywords

Carvedilol; Ejection fraction; Heart failure; Heart rate; Heart rate turbulence; Heart rate variability; Late potentials; Risk factors; Sudden cardiac death

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; LOSARTAN; SIMVASTATIN; SPIRONOLACTONE;

ADD ON THERAPY; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR RISK; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE POTENTIAL; HEART RATE VARIABILITY; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; QRS COMPLEX; RADIOCARDIOGRAPHY; RISK ASSESSMENT; SUDDEN DEATH;

EID: 38049158368     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Boersma E, Manini M, Wood DA. Cardiovascular disease in Europe. Euro Heart Survey and National Registries of Cardiovascular Diseases and Patients Management 2002. European Society of Cardiology, Sophia Antipolis 2002.
2. Young JB. Sudden cardiac death syndrome and pump dysfunction: the link. J Heart Lung Transplant 2000; 19 (Suppl. 8): S27-S31.
3. th ed. Elsevier Saunders, Philadelphia 2005.
4. Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001; 110 (Suppl. 7A): 37S-46S.
5. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001; 110 (Suppl. 7A): 81S-94S.
6. McMurray J, Cohen-Solal A, Dietz R, et al. Clinical Research Initiative in Heart failure. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001; 3: 495-502.
7. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-450.
8. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453-8.
9. Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 1999; 353: 1390-6.
10. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32: 197-204.
11. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-7.
12. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signalaveraged electrocardiogram. J Am Coll Cardiol 1991; 18: 687-97.
13. Wytyczne ACC/AHA/ESC 2006. Wytyczne dotycza̧ce postȩpowania u chorych z komorowymi zaburzeniami rytmu serca i zapobiegania nag?emu zgonowi sercowemu - wersja skrócona. Kardiol Pol 2006; 64: 1373-415.
14. ACC expert consensus document. Signal-averaged electrocardiography. J Am Coll Cardiol 1996; 27: 238-49
15. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102: 546-51.
16. Reiter MJ. Beta-adrenergic blocking drugs as antifibrillatory agents. Curr Cardiol Rep 2002; 4: 426-33.
17. Nessler J. Nag?a ?mier? sercowa w niewydolności serca. In: Piwowarska W (ed.). Nagła śmierć sercowa. Via Medica, Gdańsk 2005: 31-40.
18. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997; 15: 3-17.
19. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 Pt 2): 3S-10S.
20. Lombardi F, Mäkikallio TH, Myerburg RJ, et al. Sudden cardiac death: role of heart rate variability to identify patients at risk. Cardiovasc Res 2001; 50: 210-7.
21. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999; 34: 1522-8.
22. Haverkamp W, Breithardt G. Heart rate as a target for the prevention of sudden death. Eur Heart J 1999; 1 (Suppl. H): H76-H84.